Hepatitis C: evolution of diagnosis and treatment
DOI:
https://doi.org/10.57148/bepa.2024.v.21.40303Keywords:
Hepatitis C, Diagnosis of Hepatitis C, Treatment of Hepatitis C, Evolution of Hepatitis CAbstract
Hepatitis C is one of the main causes of chronic liver disease, cirrhosis and hepatocellular carcinoma. It is estimated that 58 million people have chronic infections with around 1.5 million new infections per year. In 2016, the WHO set the goal of eliminating viral hepatitis by 2030, reducing new infections by 90% and deaths by 65%. This experience report aims to presente advances in the diagnosis and treatment of hepatitis C in the period from 2000 to 2023 and discuss the challenges still present in achieving the WHO goal. The diagnosis of Hepatitis C involves the use of serological techniques for screening and molecular biology to confirm the diagnosis, in addition to evaluating the effectiveness of the treatment. The only treatment available until 2011 was the combination of pegylated interferon alfa and Ribavirin. The availability and evolution of direct-acting antiviral drugs since 2011 has contributed to advances in treatment, presenting high efficacy, a shorter period of therapy, fewer contraindications and few adverse effects. Even with these advances, only 20% of people living with Hepatitis C in the world have been diagnosed and 7% have received treatment. It is therefore concluded that to achieve the WHO goal, accessible and rapid diagnosis will be necessary, at the point of care, in addition to mass screening and treatment campaigns as part of the national surveillance program for this disease.
Downloads
Metrics
References
World Health Organization (WHO). Global hepatitis report. 2017. Available at: http://www.who.int/iris/handle/10665/255016. Accessed on: 13.dec.2023.
Mchutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. The American Journal of Managed Care. 2005 v.11,suppl10,p.S286-95.
Organização Mundial da Saúde (OMS). Estratégias globais do setor de saúde sobre, respectivamente, HIV, hepatite viral e infecções sexualmente transmissíveis para o período de 2022–2030. Genebra, Suíça: Organização Mundial da Saúde, 2022.
Ministério da Saúde (MS). Secretaria de Vigilância em Saúde e Ambiente Ministério da Saúde. Departamento de HIV/Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis. Boletim Epidemiológico - Hepatites Virais, Número Especial. Brasilia: MS; 2023. Avaiable http:// https://www.gov.br/aids/pt-br/central-de-conteudo/boletins-epidemiologicos/2023/hepatites-virais/boletim-epidemiologico-hepatites-virais-_-2023.pdf/view
World Health Organization. Hepatitis C [Internet]. Who.int. World Health Organization: WHO; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, et al. Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing. New England Journal of Medicine. 2004 Aug 19;351(8):760–8.
Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology. 2020 Nov;73(5):1170–218.
World Health Organization (WHO). Global health sector strategy, 2016-2021.Available at: http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.Accessed 17.nov.2023.
El-Serag HB. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology [Internet]. 2012 May;142(6):1264-1273.e1. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338949/
Aach RD, Stevens CE, Hollinger FB, Mosley JW, Peterson DA, Taylor PE, et al. Hepatitis C Virus Infection in Post-Transfusion Hepatitis. New England Journal of Medicine. 1991 Nov 7;325(19):1325–9.
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet Infectious diseases [Internet]. 2005;5(9):558–67. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/16122679
Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Practice & Research Clinical Gastroenterology. 2012 Aug;26(4):401–12.
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology. 2011 Aug;55(2):245–64.
Organization WH. Guidelines on hepatitis B and C testing: policy brief. iriswhoint [Internet]. 2016 [cited 2023 Dec 13]; Disponível em: http://apps.who.int/iris/handle/10665/251330
Parisi MR, Soldini L, Vidoni G, Mabellini C, Belloni T, Brignolo L, Negri S, Schlusnus K, Dorigatti F, Lazzarin A. Point-of-care testing for HCV infection: recent advances and implications for alternative screening. New Microbiol. 2014 Oct;37(4):449-57.
Fernàndez-López L, Folch C, Majó X, Gasulla L, Casabona J. Implementation of rapid HIV and HCV testing within harm reduction programmes for people who inject drugs: a pilot study. AIDS Care. 2016 Mar 23;28(6):712–6.
Spradling PR, Tong X, Rupp LB, Moorman AC, Lu M, Teshale EH, et al. Trends in HCV RNA Testing Among HCV Antibody–Positive Persons in Care, 2003–2010. Clinical Infectious Diseases [Internet]. 2014 Oct 1 [cited 2020 Jun 10];59(7):976–81. Available from: https://academic.oup.com/cid/article/59/7/976/2895809
Yehia BR, Schranz AJ, Umscheid CA, Lo Re V. The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. Rizza SA, editor. PLoS ONE. 2014 Jul 2;9(7):e101554.
Patel RR, Vellozzi C, Smith BD. Results of Hepatitis C Birth-Cohort Testing and Linkage to Care in Selected U.S. Sites, 2012–2014. Public Health Reports. 2016 May 1;131(2_suppl):12–9.
Brasil. Ministério da Saúde. Portaria n° 221, de 13 de julho de 2011. Dispõe sobre protocolo clínico e diretrizes terapêuticas para hepatite viral C e coinfecções. Secretaria de Vigilância em Saúde; Brasilia: MS; 2011. Avaiable http:// https://bvsms.saude.gov.br/bvs/saudelegis/svs/2011/prt0221_13_07_2011.html
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. New England Journal of Medicine. 2014 May 15;370(20):1879–88.
Liang TJ, Ghany MG. Current and Future Therapies for Hepatitis C Virus Infection. New England Journal of Medicine. 2013 May 16;368(20):1907–17.
Zeuzem S, Schmidt JM, Lee J, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnoverin vivo. Hepatology. 1996 Feb;23(2):366–71.
Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology. 1997 Jul;26(1):226–31.
Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. The Lancet. 1998 Oct;352(9138):1426–32.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (London, England) [Internet]. 2001 [cited 2019 Dec 21];358(9286):958–65. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/11583749
Lindsay K. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001 Aug;34(2):395–403.
Sarrazin C, Manns MP, José Luís Calleja, J. García‐Samaniego, Forns X, Kaste R, et al. HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. PLOS ONE. 2016 Dec 28;11(12):e0168544–4.
Morrow T. New hepatitis C drugs. Major killer disease comes under control. American Journal of Managed Care. 2014 v.23, n.1,p.49-50.
Chayama K, Hayes C. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy. Viruses. 2015 Oct 13;7(10):5328–42.
Tamori A, Enomoto M, Kawada N. Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators of Inflammation. 2016;2016:1–11.
Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology. 2018 Aug;69(2):461–511.
Compri AP, Silva VCM, Lemos MF, Oba IT, Moreira RC. Resposta virológica sustentada às drogas de ação direta de segunda geração para hepatite C. BEPA Boletim Epidemiológico Paulista. 2020 Apr 30;17(196):3–12.
HEPATITIS C MEDICINES [Internet]. [cited 2023 Dec 15]. Available from: https://unitaid.eu/assets/HCV-Medicines-Landscape_Aug-2017.pdf
D’Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct-acting antivirals: the endgame for hepatitis C? Current Opinion in Virology. 2017 Jun;24:31–7.
Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology & Hepatology [Internet]. 2019 Feb;4(2):135–84. Disponível em: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30270-X/fulltext
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Gabriela Nardini Allarcon, Marcilio Figueiredo Lemos, Vanessa Cristina Martins Silva, Clovis Roberto Abe Constantino, Adriana Compri
This work is licensed under a Creative Commons Attribution 4.0 International License.
